Let's double-check all details, spelling of drug names, numbers, speaker names, roles, etc. 1.

Prashant Nair: Prashant speaks first: "Good morning everyone. Thank you for joining us today to discuss Biocon's fourth quarter and full year results for financial year 2026..."

Wait, at the end: Operator says: "I would now like to hand the conference back to Mr. Prashant Nair for closing comments.

Thank you and over to you, sir." Then Prashant: "Yeah, thanks, Michelle.

Thank you, everyone..." Is Prashant's role stated on the call?

Let's check Prashant's opening: "Let me now introduce the management team on today's call. We are joined by Biocon Chairperson Dr.

Kiran Mazumdar-Shaw, Mr. Shreehas Tambe, CEO and Managing Director of Biocon Limited, Mr.

Kedar Upadhye, CFO of Biocon Limited, along with other senior members of our management team." Prashant's role is not stated, but his name is given at the end ("Mr.

Prashant Nair"). So "Prashant Nair:".

Introduced as: "Biocon Chairperson, Dr. Kiran Mazumdar-Shaw" "And now I would like to hand over the call to Kiran for opening remarks.

Over to you, Kiran." So: "Kiran Mazumdar-Shaw (Chairperson):" "Operator:" (Note: Prashant calls her Michelle at the end: "Yeah, thanks, Michelle."

, but the rule says: `Use "Operator:" for the conference operator.`) Operator introduces: "The first question is from Neha Manpuria.

Please introduce yourself and proceed with your question, ma'am." Neha: "Yeah, thanks for taking my question.

This is Neha from Bank of America..." Label: "Neha Manpuria (Bank of America):" Shreehas answers: "Let me answer that, Kiran...

Can I go ahead?" "Let me respond to that, Neha..."

Introduced earlier as: "Mr. Shreehas Tambe, CEO and Managing Director of Biocon Limited" Label: "Shreehas Tambe (CEO & Managing Director):" (or "Shreehas Tambe (CEO and Managing Director):") Introduced earlier as: "Mr.

Kedar Upadhye, CFO of Biocon Limited" Neha: "And Kedar, how should we think about..." Kedar answers: "Yeah, that's true, Neha..."

Label: "Kedar Upadhye (CFO):" Operator introduces: "As there is no response, we will move on to the next question, which is from Damayanti Kerai. Please introduce yourself and proceed with your question, ma'am."

Damayanti: "Hello. Good morning, all..."

Label: "Damayanti Kerai:" (firm not mentioned by her, though Operator introduced her name). Operator introduces: "The next question is from Sanjay Kohli.

Please introduce yourself and proceed, sir." Sanjay: "Yeah, this is Sanjay from Goldstone Capital.

We are a private investment group based out of the NCR region..." Label: "Sanjay Kohli (Goldstone Capital):" Operator: "We'll take the next question from Avnish Burman.

Please introduce yourself and proceed with your question." Avnish: "Yeah, hi.

Good morning. This is Avnish Burman from Weakar, yeah..."

(or "V-Care"? "Vehkaria"?

Avnish Burman from Baker / B&K / Elara? Spoken: "from Vikara, yeah" / "from Vicaria" -> let's check exact spoken words: "Avnish Burman from Weakar, yeah" -> wait, let's listen/check: "Avnish Burman from [Veker?]

, yeah"). Label: "Avnish Burman:" or "Avnish Burman (Vekar):"?

Let's check rule: "When the operator introduces the next caller by name and firm... use that identity".

Here operator didn't state firm, caller said "This is Avnish Burman from..." .

Operator: "The next question is from Siddharth Negandhi. Please introduce yourself and proceed."

Siddharth: "Hi, thanks for the opportunity. This is Siddharth Negandhi from CWC..."

Label: "Siddharth Negandhi (CWC):" Operator: "The next question is from Tushar Manudhane. Please introduce yourself and proceed."

Tushar: "Thanks for the opportunity. This is Tushar from Motilal Oswal..."

Label: "Tushar Manudhane (Motilal Oswal):" Operator: "The next question is from Imtiaz Shefuddin. Please introduce yourself and proceed, sir."

Imtiaz: "Can you hear me? ...

Yes. Hi, this is Imtiaz Shefuddin from Barclays..."

Label: "Imtiaz Shefuddin (Barclays):" Operator: "The next question is from Surya Patra. Please introduce yourself and proceed."

Surya: "This is Surya from PhillipCapital. Thank you for this opportunity..."

Label: "Surya Patra (PhillipCapital):" Operator: "We'll take the next question from Vishal Manchanda. Please introduce yourself and proceed, sir."

Vishal: "Hi, good morning. This is Vishal from Systematix..."

Label: "Vishal Manchanda (Systematix):" Operator: "The next question is from Nitin Agarwal. Please introduce yourself and proceed, sir."

Nitin: "Hello... Yeah.

Shreehas, on the insulin business..." Label: "Nitin Agarwal:" - Plain text, one paragraph per speaker turn, each starting with "Speaker Name: " (or "Speaker Name (Role): ") - No timestamps, no headers, no commentary, no markdown.

- Only the transcript text (no preamble, no closing remarks, no markdown fences or blockquotes). Good morning, everyone.

Thank you for joining us today to discuss Biocon's fourth-quarter and full-year results for financial year 2026. Our press release and the investor presentation relating to today's results have been filed with the exchanges and are also available on our website for your reference.

As a reminder, in fiscal '25, we had certain one-time benefits, including contributions from generic lenalidomide in the US and divestment of our India branded formulations business. To enable a like-for-like comparison, we have provided adjusted financials excluding these items in our fact sheet and presentation.

Let me now introduce the management team on today's call. We are joined by Biocon Chairperson, Dr.

Kiran Mazumdar-Shaw; Mr. Shreehas Tambe, CEO and Managing Director of Biocon Limited; Mr.

Kedar Upadhye, CFO of Biocon Limited; along with other senior members of our management team. We will begin with opening remarks from Kiran, following which we will open the call for an interactive Q&A session.

Please note that this call is being recorded. The recording will be made available on our website within a day, and the transcript will be shared shortly thereafter.

Before we begin, I would also want to remind everyone about the safe harbor related to today's call. Comments made during the call may be forward-looking in nature and must be viewed in relation to the risks that our business faces that could cause our future results, performance, or achievements to differ significantly from what is expressed or implied by such forward-looking statements.

Now, I would like to hand over the call to Kiran for opening remarks. Over to you, Kiran.

Thank you, Prashant, and good morning, everyone. I would like to start by saying that Q4 marked a strong close to an important year for Biocon.

We delivered a resilient operating performance despite a very volatile macro environment, while also completing one of the most significant strategic transitions in our journey. The external environment remained challenging throughout the quarter, with geopolitical uncertainty continuing to impact supply chains, logistics, and energy costs.

What stands out for me is the way our team stayed focused on execution and delivered a good performance, reinforcing the underlying resilience of our business. I want to particularly acknowledge our team for the way the integration of our biosimilars and generics business was concluded seamlessly in under 100 days, with no disruption to business operations, customers, or patients.

It reflects the strength of our execution engine and the discipline with which we run this organization. This was a very complex organizational and financial undertaking, and it has been delivered with speed, discipline, and clarity of intent.

With this, we are now operating as one unified biopharma entity with a stronger balance sheet, improved leverage metrics, and a more integrated global commercial footprint. As I have said before, this is a value-accretive step that creates a simpler, stronger, and more efficient operating model, unlocking synergies across our supply chain, commercial engine, and capital allocation.

We are now moving from a phase of integration and investment to one focused on execution, operating leverage, and value creation. From a capital and investment perspective, the heavy lifting is largely done and behind us.

Over the past few years, we have invested materially to build global scale capabilities and capacity, particularly in biosimilars, insulins, peptides, and complex generics. As we stand today, this major investment phase is substantially complete.

The emphasis now is on improving utilization, expanding margins, and driving steady improvement in return on capital employed. A key pillar of this transition has been the continued strengthening of our balance sheet.

During the year, we made further progress on deleveraging and improving financial flexibility. With the buyout of minority shareholders in Biocon Biologics and the repayment and refinancing actions already taken, we now have full economic ownership of our largest growth engine.

Importantly, interest cost savings have begun to accrue, and the full annualized benefit will be visible from FY27, further supporting profitability and cash generation. Now let me come to key business developments.

Now, before moving to the financial performance, let me highlight a few business developments that reinforce the strategic progress we are making across our portfolio. We achieved important product approvals in biosimilars and generics, further strengthening our presence in regulated markets.

We received Health Canada approvals for Bosaya and Vegzelma, our denosumab biosimilars to Prolia and Xgeva, expanding our footprint in bone health and oncology and adding momentum to this important franchise. After the close of the quarter, we also announced the US commercial launch of Bosaya and Ochrezel, our denosumab biosimilars in the US.

We also received US FDA approvals for liraglutide during the quarter, covering both diabetes and weight management indications. Taken together, these developments reflect continued progress in advancing our portfolio across oncology, immunology, and metabolic diseases, while steadily translating approvals into commercial scale-up.

Let me now walk you through the financial highlights. In FY26, the group delivered a biosimilars-led 10% year-on-year growth in operating revenue, excluding the one-time bolus of generic lenalidomide in Q4 FY24—'25.

Biosimilars grew 12% year-on-year, and generics, excluding lenalidomide, was 13% growth year-on-year. CRDMO business grew 2% year-on-year.

EBITDA was at 1,073 crores, with a margin of 23%. Adjusted for generic lenalidomide in the base, this was up 29% year-on-year.

The improvement was primarily driven by favorable revenue mix and operating leverage benefits in biosimilars. The reported net profit for the quarter before exceptionals was 179 crores.

For FY26, adjusted for generic lenalidomide, operating revenues and EBITDA grew at 13% and 25%, respectively. EBITDA margins stood at 22%, which is up around 200 basis points year-on-year on a like-to-like basis.

Reported net profit for FY26 before exceptionals stood at 436 crores. I would now like to discuss our business performance in a segmented manner.

Let me start with biosimilars. The biosimilars business enters FY27 on a strong footing, with a broader portfolio, expanding global footprint, and improving profitability positioning it well for the next phase of growth.

In North America, Yesintek continued to gain traction in the US market—this is our biosimilar ustekinumab—with growth supported by expanding formulary coverage and increasing physician confidence. The brand continues to build momentum in line with expectations, reinforcing our confidence in its longer-term potential.

We also made progress with the launches of Bosaya and Ochrezel, which is our biosimilar denosumab in the US. Now moving to Europe, during the quarter, we broadened our immunology footprint with the launch of Yesintek across multiple markets, expanded our ophthalmology presence with Yesafili, which is our biosimilar aflibercept in the UK and other key countries, and continued to expand our oncology franchise with Abevmy, which is our biosimilar bevacizumab, and Ogivri, biosimilar trastuzumab.

We also launched Efrawxy, which is our biosimilar denosumab for bone health in Germany. On the regulatory front, Swissmedic approved our ustekinumab biosimilar Yesintek, and in the UK, the MHRA granted approval for the Yesintek autoinjector, enhancing patient convenience and supporting broader uptake.

Coming to emerging markets, execution during the period was driven by tender wins, new product filings, and selective launches across priority markets. We continue to scale the business through a mix of self-led operations in key countries and partnerships in others.

Coming to segment financials, biosimilars revenue for Q4 FY26 stood at 2,756 crores, representing a 12% year-on-year increase driven primarily by advanced markets. EBITDA for the quarter stood at 720 crores, representing growth of 33% on a year-on-year basis.

This translates into an EBITDA margin of 26%. Margins in this segment continue to reflect the benefits of improved revenue mix as well as operating leverage.

R&D investments for the quarter stood at 7% of revenues, reaffirming our ongoing commitment to innovation and pipeline advancement. For FY26, biosimilar revenues and EBITDA grew at 16% and 40%, respectively, on a like-to-like basis.

Now coming to generics. We secured multiple approvals across key markets, led by products in diabesity, oncology, and immunology.

This included liraglutide across the US which is generic Victoza and generic Saxenda, Europe generic Victoza, and Australia generic Saxenda. In addition, we received approval for everolimus tablets in the US and for tacrolimus across Latin American markets.

When it comes to segment financials for generics, revenues stood at 847 crores, and adjusted for the one-time generic lenalidomide supplies in Q4 of FY25, revenues grew 13% year-on-year, driven by generic liraglutide sales in Europe. EBITDA stood at 75 crores.

EBITDA margins were at 8%, improved nearly 300 basis points over Q3 of this fiscal, driven by higher volumes and operating leverage. For FY26, adjusted for generic lenalidomide, generic revenues and EBITDA grew 17% and 73% year-on-year, respectively.

Now coming to our final part of my presentation, which is our CRDMO business. In Q4 FY26, revenues from operations were at 1,037 crores, up 2% year-on-year and up 13% quarter-on-quarter.

FY26 revenue from operations were at 3,739 crores, up 3% year-on-year. Operating EBITDA margin at 25% for the year was in line with Syngene's revised full-year guidance.

Overall numbers reflected the specific impact from a single large-molecule biologics client, with the underlying business showing steady momentum. Syngene completed 14 client and regulatory audits during the quarter, bringing the full-year total to 85.

It also obtained the GCP NABL accreditation during the quarter, reinforcing adherence to globally recognized standards for clinical research and data quality. I now would like to wrap up with my concluding remarks.

To conclude, FY26 marked a pivotal year for Biocon. With the integration complete, the major investment phase behind us, and the balance sheet significantly strengthened, we have entered the next phase of our journey.

Our focus now is firmly on disciplined execution, driving growth, expanding margins, and delivering a sustained improvement in return on capital. As we look ahead to FY27, we expect to increasingly benefit from the foundations that have been laid, with performance improving progressively as the year unfolds, especially as our new products scale up meaningfully in the second half.

In biosimilars, recent launches across markets are beginning to scale, which should support continued growth and operating leverage. In generics, the emphasis will be on improving profitability as newer assets stabilize and utilization improves.

At Syngene, following the challenges seen in FY26, the focus remains on execution and translating recent investments in CRDMO capabilities into more stable performance. With a stronger foundation in place, we believe Biocon is well positioned to deliver consistent performance and long-term value creation.

With that, I now invite questions.

Thanks for taking my question. This is Neha from Bank of America.

Two questions from me. First, on the biosimilars revenue, given that we spoke about execution in the opening remarks, how should we think about FY27, FY28, given we have had some launches in the fag end of '26?

Also, there was an impact of the planned shutdown that we took in third quarter and a bunch of launches, but we haven't really seen material improvement in biosimilars revenue, fourth quarter versus second quarter, if that is the comparable number, given we have also seen market share increases. Is it fair to assume that full stabilization of that disruption that we saw in the third quarter is not yet done?

Let me answer that, Kiran. Can I go ahead?

Let me respond to that, Neha. I think thank you for your question.

I think this is important to look at. When we did the Q3 last quarter, we had indicated, like you rightly said, that we are slowing down some of these things to get ready for a greater supply capability in the coming fiscal.

I think if you look at the numbers between Q3 and Q4, you are seeing a sequential change where we moved from a quarter which was $279, $280 million to about $300-plus million this quarter. There's a sequential growth of 12% that you're seeing on a rupee basis in the revenues.

That's the first indication. You're also seeing the margins stable for the full-year basis, which has been consistent.

That's, I think, the first indication that the business has ramped up in the right direction. The second question that you asked is that how is it from an outlook perspective for '27, '28.

While we've not guided specifically on any numbers, I think the fact that we've got several products launching in the coming fiscal, which is '27, '28, the ramp-up starts moving from the coming financial year in '27, '28 towards the later part of the year, and that's why you set yourself up building capacity, increasing scale, and that is what you will see going through the year. Last quarter, I also said that aspart we'll start seeing a ramp-up, which will come in towards the second half of the current fiscal year, and you'll see that happen.

We've publicly stated we have a negotiated settlement date with the originator for our aflibercept launch in the United States, and you will see that play out in the coming fiscal year. We've seen tremendous success with our biosimilar ustekinumab, which continues to gain market share.

In fact, if you've seen the IQVIA numbers as of February, in the overall market, it's close to a fifth already, which is a very strong showing for a product which has several competitors there. Recent news of payers have also shown that we've been able to secure good formulary placement.

We're quite bullish about how our products are shaping up. We've said that fiscal '27, '28, as we get towards the later part of the year, we'll start seeing the ramp-up that we've prepared ourselves for in biosimilars.

Shreehas, while

I understand you don't want to give specific guidance, but if I were to think about fourth quarter FY27 exit run rate, given the launches that we have, what, in your mind, would be a comfortable number, based on the launch pipeline?

Neha, I know that you've asked that question in different ways, but I think the important thing—and again, if you go back to what I've said in previous conversations as well—that this is not a quarter-on-quarter conversation. Look at it on a broader window.

If you looked at the business that we've built over the last eight quarters or even four quarters, you will see a substantial shift. If you see just this year's numbers that we've posted on a rupee basis, there's been a 16% growth over last year, and you've just seen Yesintek, which is our biosimilar Stelara, starting to show numbers in the P&L.

You will start seeing that flow through in the second half of fiscal '27 as more products come in. I can only point you towards how we've done in the past, which is a strong showing already, and then tell you that look at the four quarters going forward, which will be a good way to see how the business ramps up.

Understood. Kedar, how should we think about deleveraging in fiscal '27 now that Biocon Biologics merger is done?

Is it fair to assume that all of the free cash flow generation that we have would be largely used for deleveraging, any color there?

That's true, Neha. I think every dollar that we generate out of free cash, the first claim is going to be to reduce the debt, and we are pretty serious about it.

If you remember, in March '25, including structured instruments, we had, in fact, more than $1.5 billion of net debt. That's down to 1.1 now.

It will hover between 1.1 to 1.2 subject to working capital, and free cash that we generate hereafter will go towards reduction of net debt, Neha. That's right.

Kiran referred to interest cost reduction. If you remember, first quarter of this year, we had booked 280 crores in that quarter.

It was trending upwards to 300 crore, and from those levels, now we are down to about 210, 220. It will have some currency impact because large part of our debt is in dollars, but in that sense, about 70, 75 crores per quarter of interest cost reduction is being reflected in the P&L now.

Got it. Thank you so much, Kedar.

Hello. Good morning, all.

Thank you for the opportunity. My first question is again on biosimilars.

First, if you can give a split for FY26 sales between developed market and rest of the world. Then if you can comment on two specific products, aflibercept, where you will be coming soon in the market as per your settlement date, there we have seen one of the earlier entrant going very aggressive in terms of taking market share, etc.

How do you see that opportunity? Second question is on aspart, which you indicated is a key product for FY27.

What kind of visibility we have in terms of higher demand or your capability to supply this product to gain meaningful market share from here on? Thank you.

I think let me respond to the first one. Kedar can come in.

In the past also, we've said our distribution is pretty diversified between advanced markets, emerging markets. If I give you a split, it's been roughly NorAm at 40, 35 in Europe, and 25 emerging markets.

You see sometimes a little bit of a shift between North America and Europe. You see sometimes North America slightly higher, but roughly 75-25, if you're asking advanced markets and emerging markets, could be between 78-22 in a particular quarter.

That's the broad split, Damayanti. Kedar can give any specifics if there's anything.

The other question that you asked in terms of our product launches is that, as I said, we are looking to bring our biosimilar aflibercept—it's branded Yesafili—to the United States in the second half of this year. I think what you rightly cited is that there is a biosimilar today and it's been quite successful.

It's a very encouraging sign because this is a niche product, a specialty one which is injected in the eyeball. One of the questions around it was, will ophthalmologists be comfortable using a biosimilar?

I think that myth's been busted that there is comfort in using that, and there is willingness to use biosimilar. It's paved that path for us.

Given our track record of high-quality products, we believe that there'll be a significant interest as we move forward. We feel good about our Yesafili launch, and as the product ramps up in fiscal '27, we'll be in a position to talk to you more about that.

Your other question was related to biosimilar aspart, insulin aspart that we talked about. Our brand name there is Kirsty.

Again, it's a product we've discussed several times with you. We see a tremendous opportunity.

We've been very careful, as it's a chronic product. We've said multiple times both for peptides and for insulin that we are very uniquely placed as the only company with a biosimilar insulin and a peptide portfolio.

We've never looked at it as a sprint. It's a marathon for us.

We have 100% share in certain closed-door networks that are there in the US already, and we've built our credibility there, and we're looking to expand that to the commercial play in the second half of this fiscal year, fiscal '27. Watch this space.

We will keep you posted on how aspart ramps up in the current fiscal year.

Thanks, Shreehas. The second question I wanted to ask is on your capital allocation going ahead.

As you mentioned, you are done with majority of investment in capex, etc., and focus ahead will be on cash generation. I just wanted to have some more color on your focus in R&D, what kind of products you can add on to your portfolio say 2 to 3 years down the line, and apart from the Malaysia plant, do you have any other capex remaining from your end?

At the beginning of the conversation, Kiran called out very clearly that we are in a space where capital allocation is largely behind us, or capital investments are largely behind us. Given that we've now merged the biosimilar businesses and the generics business, it strengthened our balance sheet right away, immediately straight out the gate.

That's happened. Operating leverage starting to kick in, which you'll see a flow through the first quarter that will come out.

You'll start seeing it. You heard Kedar talk about the fact the use of proceeds has allowed us to bring in 300 crores of interest savings over the year, which will mean 75-odd crores per quarter.

You are seeing a strengthening on the P&L. Now coming to the portfolio side, that allows you to do a lot of other things outside of this, because you're no longer making investments in capex.

You're trying to now see how you can get those assets to deliver maximum profitability for you. That's what we've done with the biosimilars business, if you tracked us, which I know you have, for the last 3 years, where we're starting to see that play out as operating leverage.

You will see that in our generics business as well, because we have a very strong portfolio that we've built in the generics business as well, which is very complementary to our biosimilar business, and that will kind of feed off the biosimilar capability we've built across several countries. That is what we expect to do: reconsolidate the business in the next four quarters and set it up for acceleration in the coming fiscal.

Shreehas, I'll get back in the queue. All the best.

Thank you, Damayanti.

This is Sanjay from Goldstone Capital. We are a private investment group based out of the NCR region.

I have a specific question on the reported numbers in the income statement. Not been able to figure out under the head items that will be reclassified to P&L later.

There's a large number of 760 for the quarter, and then which will be reclassified and which will not be reclassified about 210 crores. What exactly is this?

Sanjay, if you are referring to what is captured in the other comprehensive income, there are some adjustments that you do there which don't appear in the normal P&L. I'll take it offline.

Why don't we take it offline, Sanjay?

How do I do that?

No, no. Let's get in touch after the call.

Let's speak and we'll explain. We have full backup.

Thank you.

Thank you.

Hi. Good morning.

This is Avnish Burman from [Veker?] , yeah.

Shreehas, sir, just one question for you. In March, I think we saw some draft guidelines coming from the FDA, which talked about significantly reducing the R&D cost to get new biosimilars in the market.

I just wanted your opinion on how that impacts, one, Biocon's existing products, commercialized products, and second, the pipeline. Thanks.

Thanks, Avnish, for your question. I think you've been tracking this well.

We've been talking about this for a while, where we believe that the FDA has led the way in saying that you do not need a Phase 3 clinical trial to approve these high-quality biosimilars. That has significantly allowed us to do two things.

One is it has reduced the development costs by 50%, it's halved the development costs, and it's accelerated products from a development standpoint by at least 3 to 4 years, which is again cutting down time for products which can get into market. The common belief then is that it's lowered the bar to the market, which is incidentally not accurate, because what has happened is, while the clinical Phase 3 trial requirement has been taken away, there has been a expectation of higher comparability standards, analytical comparability standards that have been set up, so that you prove before you get to the clinical stage that your product is highly similar to the originator drug.

The companies who've been developing this are clearly at an advantage. While it does look attractive to get into this market, and which is why you're seeing also lots of interest in this, which is again another thing we've said for a while that biosimilars is the next growth area, and you're seeing investments happen again with a lot of interest, it does give companies like Biocon an advantage given our proven track record in CMC comparability and analytical characterization, which will be brought to bear as we go forward.

I understand it being beneficial for Biocon in terms of the products that you are still yet to bring in the market. What about the products where Biocon has a good position in the market?

Where you are the incumbent, and you might be facing some incremental challenges in those products?

We do not see an incremental challenge, because the products that we already have brought to market, and if you were to look at the products that have been in the market have got a very strong leadership position. If you look at the ones in the US, which we usually or selectively track on this call, our oncology portfolio, which is in the medical benefit space, have fourth of the US market today.

One is to get an approval, the other is to be able to reliably supply it, third is to do it consistently, and fourth is to be able to be a reliable partner to the physicians, to the healthcare givers, and be a reliable supplier to the patient who's looking forward to these products. That takes time.

Credibility is built over a period of time. I think we've been fortunate.

It is something that we've worked hard towards. Being a fully integrated player, Avnish, has given a lot of levers to Biocon to operate and be successful in this space.

We do not see a challenge because of these revised guidelines. In fact, it's an advantage Biocon the way I see it.

Thanks. Thanks a lot.

Hi, thanks for the opportunity. This is Siddharth Negandhi from CWC.

Couple of questions. One, could you give us an understanding of the constant-currency sales in each of the divisions?

The second one was if you could give us some color in terms of market shares and the $200 million benchmark that you had shared last year. If you could give us an update on both of those, the market shares as well as the number of products that are above $200 million in biosimilars.

Maybe I can take that. Siddharth, the growth numbers in rupees that we have reported, if you could roughly take about 3%, 4% out, you will get the dollar number.

For example, biosimilars, we are seeing it's 12% growth year-on-year in this quarter. The dollar growth will be about 7% or so.

That's the constant-currency number. In terms of the products that were beyond 200 million, we have done good progress.

Insulin now has crossed 300 million actually this year. That's the bracket that it has crossed.

That includes glargine, aspart, human insulin, dsdp. Totally insulin franchise is now beyond 300 million.

Adalimumab is now beyond 250 million, and pegfilgrastim, trastuzumab are hovering around 200 million or slightly lower than that. Bevacizumab has crossed 100 million now.

This is without contribution from US because the launch has just been made. Then there are products like etanercept, Yesintek is inching up now.

That's how, Siddharth, the progress on these four products that we had spoken last year.

Great. Kedar, if you could also help with any update on the market shares that you'd shared last year.

The margin improvement that we're seeing in the generics business adjusted for Revlimid, just wanted to understand, is that a function of the change in the API and formulation mix, or is there something else there?

Your first question, Siddharth, was about the biosimilars margin? Sorry, I missed that.

I think he wanted market share.

Market share. Market share.

Market shares are steady. I think oncology market shares are steady around 23% to 25%.

Glargine market share is also what's reported is about 11%, so that's fine. The next question was in terms of generics margins.

We had guided for the fact that from the first quarter till fourth quarter sequentially, as the sales do inch up, there will be a margin improvement. I think quarter four, you are seeing more than 10%, roughly 10% EBITDA margin, and that's because of both overall sales have gone up, you have operating leverage benefit as the facilities get utilized, and there is a positive product mix as well.

Thanks. Thanks, Kedar.

Thank you.

Thanks for the opportunity. This is Tushar from Motilal Oswal.

Just on the biosimilars, what could be the capacity utilization currently?

Kedar, do you want to take that?

I think, Tushar, it will obviously vary plant by plant, there is no one number that we could give it to you now. I think capacities do remain healthy, and like what we mentioned last quarter in terms of upgrades and things like that, we are getting ready for the growth now.

Within each location, like for example, Malaysia now we have two lines, in Bangalore, there are multiple suites, as we have been speaking. There is no one number, but I think utilizations are healthy.

The direction which I'm trying to get through is that while we have a very robust portfolio and subsequent new approvals that might come through, but from a capacity standpoint, do we really need further capacity expansion, or the current capacity would be good enough to drive growth for FY27, '28 in particular?

As the Malaysia doubles both for drug substance and drug product, I think we are fine there. Plus, we have some external CMOs as well, as you know.

In Bangalore, I think there could be minor debottlenecking here and there, but as of now, we don't see any need for a large greenfield capex, Tushar.

This Malaysia doubling, the timeline for this?

The DP has happened. The line two is getting qualified as we are speaking, and will get operational soon.

DS, the drug substance doubling will happen towards the end of this financial year.

Effectively, for full year '27, compared to what we have in '26, this DP Malaysia in particular is what will drive and some amount of debottlenecking at Bangalore from a capacity standpoint is what will drive growth for FY27, is that the safe assumption?

Yes, and after that as well. Correct.

Got it. Just to complete this point, considering the earlier commentary in terms of product launches largely second half FY27, is it that the first half is going to be largely stable, maybe currency benefit is what will drive growth for biosimilars business?

We don't guide specifically, Tushar, but like what Shreehas said, you should budget for incremental growth from new launches more towards second half. Yes, there will be a currency advantage in the first half.

Just to add to what Kedar said, Tushar, just now you asked about the capacity and then the linkage to aspart to that. Our Malaysia drug product line comes on stream this quarter, and as you bring products, as I said, to the market, this line starts supplying product to the market, which is why the ramp-up you will see happen through the year.

As product moves up, you will see it ramp up towards the later half. That's the conversation we're having.

The capacities are already invested in, and you will see that ramp-up as it goes. It's not like that there is no demand or capacity in the beginning.

It just ramps up because the demand is set up and capacity comes on stream starting Q1.

Great, sir. Just lastly to connect on this particular aspect, will this require reinspection, or we are good to go in terms of commercials?

No, no, we are good to go on commercials. Yes.

Great. Great, sir.

That's on biosimilars. On the generics side, just to understand, good amount of investments largely behind both in terms of capex as well as product development, and now we are scaling up in terms of business.

Without any let's say a niche product so to say, how to think about the scale-up of this business and subsequently the margin improvement? Maybe if you can just help us understand what's the gross margin currently, and how the operating leverage will play out let's say in the coming time?

I lost the question in between, Kedar. Can you step in, then I can step in after that?

Go ahead.

Yeah. I think, Tushar, the gross margins are in early 40s, and that's the two-third API, one-third generics, that's kind of a split today.

As the GLP-1 revenues, which were about less than 10% of the overall business last year in FY26, that will scale up, and multiple launches that we alluded, that will scale up. I think, Shreehas, the question was, what's the direction on generics growth and margins?

Yeah.

Tushar, I think if you heard the opening remarks that Kiran started with, if you want to look at the base business itself, I think that is where you're starting to see growth on a sequential basis, which is the first good indicator that you're seeing, leaving aside the exceptional that we saw on lenalidomide. The focus for us going forward is very clearly going to be on margin improvement, because we built state-of-the-art facilities.

These facilities have now come on stream, and as demand ramps up and capacity utilization is there, you will start seeing the margin improvements flow through. The focus is clearly going to be on making sure that operating leverage kicks in in the coming quarters.

Sir,

that would be supported by the scale-up of existing product, or we will require new approvals to come through?

It is a mix of both. Many of these products, the approvals come in ahead of time, unlike the biosimilars business where product approval and launch are fairly close depending on the patent negotiations or the patent dance.

The generics portfolio benefits from an earlier visibility, and hence we are looking forward to launches in the coming years, which is why the capacity investment was done ahead of time, allowing us to do a lot more things. If you just refer to the peptide portfolio, now Biocon would be set up in a very different way where you have fungibility for drug substance for the peptide portfolio as it gets into the fermentation space, which is again hardly any competition there, and then you have fungibility for the drug product facilities, which have also been set up.

As that demand ramps up in the coming quarters and coming years, you will start seeing better utilization and a better return on that investment that we've made.

Got it, sir. Just lastly, bevacizumab, I missed the sales for FY26, if you could just repeat.

It's 100 million, Tushar. It's entered in that bracket now.

This is without contribution from US geography.

Got it, sir. Thanks a lot.

That's it from my side.

Can you hear me?

Yes. Hi, this is Imtiaz Shefuddin from Barclays.

A couple of questions from me with regards to your US dollar bonds. Would you be able to provide some color on your hedging policy?

I know you have currency benefits, but any specific hedging policy you have on the US dollar bonds? That's my first question.

Imtiaz, on the bonds, we don't have to hedge because we have a natural hedge. We are largely a dollarized company, we have significant dollar cash flows.

We don't hedge our loan book, actually.

Good, sir. Secondly, also on your US dollar bonds, your bonds become callable from October this year, although at a premium price.

How are you thinking on the bonds given that your US dollar bonds are at 6.67% coupon and you have talked about a focus on reducing your average cost of debt?

Imtiaz, we are tracking the situation. We are happy that bonds are trading at a premium.

You must have noted in the last few months, both the rating agencies have upgraded the rating. We are watching the situation.

I think we have to evaluate whether it makes sense to pay the call premium in the first year. There's 50% call premium in the first year, 25% in the next year.

That's the 5NC2 structure that we had. At this point of time, Imtiaz, we are watching the situation.

We are happy with the way things have progressed, and we are happy with the upgrades, and the idea will be to continue on this journey.

Great. Thank you.

Thanks, Imtiaz.

This is Surya from PhillipCapital. Thank you for this opportunity.

Couple of questions. First, with the ramp-up that we are likely to see in the biosimilar portfolio, although we have started seeing strong growth in the US business front given the kind of products that has been launched during FY26 and the products like the Eylea that is there, along with the denosumab contribution in the current financial year.

What is the kind of a momentum that we would see for the US business, and what is the likely share of US business in FY27 versus FY26? Because basically what we are seeing that, okay, so far it is the non-US would have supported the growth meaningfully, but now there is a strong lever for the US to perform and really contribute meaningfully to the margins also.

How the mix likely to see the shift?

Thanks, Surya, for your question. I think this is very important.

Two things that I will say: one is in the past, you've heard me say that market share is not necessarily the only proxy for success, and the other thing that I've said is that market share and ASP have always been adversely proportional in a medical benefit product, and we've been very clear about making sure that we will grow business profitably. Growth is only when it's profitable.

We've been very careful as we've picked up market shares. The medical benefit products that you see today, where we've had a fourth of the market, we've focused on making sure that we've retained that profitably.

We would be fine if that market share is not the proxy for where we are, but we will grow that, Surya, slowly. The market has examples where you have tried to gain market share very quickly, but then you crash out also very fast, because that's how the medical benefit space operates, because you have a declining average selling price, which is very contrary to how the pharmacy benefits space operates.

We can have an offline discussion to walk you through the model. Last quarter, when we had a conversation on how we are approaching denosumab, which is another important asset that we've launched in the Kiran just talked about it in her opening remarks, it's branded Bosaya and Ochrezel—we will be very careful in doing it, because one of the brands is in the pharmacy benefit space, and the other one is in medical benefit.

Last quarter, as I was saying, our chief commercial officer, Matt Erick, walked the team on the call about our strategy to commercialize it. Our focus is always profitable growth and not necessarily market shares.

We'll be very careful in doing that. I wouldn't necessarily look at market shares as the only proxy for success.

Numbers will play out over the year, and you will see them being more enduring over a period of time. I would advise you to look at that.

My guidance would be look at a broader quarter rather than trying to look at this as a quarter-on-quarter immediate launch and an impact on market share kind of a business.

Sure, sir. Sir, any clarity on the exclusivity that we could have for Eylea now?

For Eylea, our biosimilar position that we've got, as I said at the beginning, there is a biosimilar that is there in the market already, and we've seen encouraging numbers from there, which tells us that we can actually commercialize that market very well, which is good news. The second part is our terms for negotiation and settlement are confidential, and likewise, we wouldn't want to comment on others.

We believe we will be in a good position when we get out of the gates for the launch in the US. As that plays out, Surya, you can see it come through, but it wouldn't be fair on my part to comment on the terms of the settlement.

Okay. This insulin opportunity has been a kind of a or the kind of situation, market situation in the global market given the GLP play and all that.

This is making us or positioned us very strongly in the insulin side, and the doubling capacity what we are talking of also that is also complementing that story. Hence, now this expanded capacity what we are talking, sir, what is the kind of a lever that it is adding to the the current insulin revenue of around $350-odd million what Kedar just mentioned?

Again, we've been very clear right from the beginning that we're, in that sense, the only insulins company which has a peptides portfolio, and that's something that we've heavily indexed on. We've built a very strong insulins franchise globally.

There are several markets, I know we discussed the US and certain European countries in this call, but there are several countries in emerging markets where our market shares are in excess of 50%, and we're a very responsible supplier. We've continued to grow that franchise.

In dollar terms, we've refrained from giving numbers, but we see a very encouraging response in terms of how the products grown, both for the long-acting and the short-acting insulin, or even the recombinant human insulin, which I'm constantly reminded is a very large requirement in several countries. We remain committed, Surya, and we made these investments ahead of time, you will see us get those products to market.

It'll start playing out in the numbers starting second half of this year is our view.

Last one question from my side, sir. Having seen the integration well and also having done investment into the generics in advance, what should be the investment priorities for FY27 now for you?

See, I think if you heard Kiran in the beginning, most of our investments are behind us, Surya. Our focus is always going to be, now that you have a strong balance sheet and you're looking to have operating leverage that's come in, the focus is going to be capital allocation at this stage.

We'll only focus on seeing how you profitably, sustainably grow the business. We're not looking at very big-ticket greenfield kind of expansions, because we don't need it to support the business plan that's going forward.

Focus is now on execution, consolidating the business, and walking it through the quarters as we bring the business up in a sustainable manner. You will see the EBITDA growth that you've seen already in the margin profile improvement.

The focus will be to sustainably do that on a consistent basis.

Sure. That means capex is likely to subside.

Yes, we've already said that.

Yeah. Sure.

Thank you, sir. Wish you all the best.

Hi, good morning. This is Vishal from Systematix.

Can you break up your biosimilar sales between US, emerging US, Europe, and the rest of world?

Vishal, for the last two quarters, the mix of North America is slightly higher. In the past, we have said North America is about 40, Europe and a little bit of Japan, ANZ 35, and emerging market 25.

Our hunch is over the long term, that's how it will stay. Last two quarters, because of prioritization and higher growth, North America is higher, and that helps us obviously in the margins.

Let's watch how this pans out. We obviously want all three geographies to grow equally.

Which would be your largest product as of now within the biosimilar portfolio?

Within the biosimilars, NorAm led by US is about 46% this quarter. Last quarter it was slightly higher.

And

Kedar, I think his question was on products. I think we've given the product piece already, which products.

Yeah. Product-wise globally, Vishal, we have already spoken: the insulin franchise, adalimumab.

Now we don't break products into geography. That will be too much of granularity,

but happy to talk Globally, which is your largest biosimilar product?

We just spoke about, Vishal. Total insulin franchise globally has crossed 300 million.

Adalimumab globally again is beyond 250 million, and then the other two key oncology assets are little less than 200 million. Bevacizumab is now 100 million-plus, and then there is Yesintek, there is etanercept.

That's the mix.

Are we seeing annual price decline in the base portfolio, or that is more or less flat? If you could share some color on the base business erosion, or that remains flat?

I think each geography has its own pattern. Europe is usually very steady, and North America, because of the strategy that we deployed on the ASP for the last 3 years, we have not seen much erosion.

Yes, I think we should budget for some erosion, Vishal, but tough to tell you one specific number because it will vary depending upon the product life cycle.

Understood. Just one final one.

What percentage of our biosimilar sales is manufactured in-house?

The whole portfolio is in-house except adalimumab and etanercept. Yeah.

We do take some help from CMOs in the human insulin, but we can come back to you with a specific number, Vishal.

Got it. Thank you very much.

Thank you.

Hello?

Yeah. Shreehas, on the insulin business, can you just give us a sense, you talked about we have now the short-acting, long-acting, as well as recombinant insulin.

What is the addressable market globally across these three sort of insulins put together from a size perspective?

From a dollar number perspective, I think we can get you the numbers, but it will be around that $7, $8 billion overall insulin. RHI is about a billion and a half globally, and you'll see the other two be in the region of about 3 billion.

The fact is that these numbers are not as reported by IQVIA. It changes significantly as you get towards emerging markets and tender businesses.

Needless to say, it is a significant business with just the originators and limited number of players. In the US, you have just us which has a biosimilar insulin.

That's a tremendous franchise to be focused on. There are other attractive assets that certain innovators are focused on, which interests them.

That leaves a very large playing field for Biocon.

Shreehas, on that account, there've been off late some recent approvals with Chinese companies which have come through. How should one think about that?

In the past, Chinese have had a tendency to disrupt markets. Do you foresee some of those challenges for us in the broader insulin space?

I think the first indication of this is that it signals the fact that what we've been saying, and it validates it, that it's a extremely attractive market for people to come in. We've seen certain European companies wanting to enter as well, partnering with other companies from China.

This is clearly what we've been saying. It's a tremendous opportunity.

The product remains in business, in requirement several decades after it's commercialized. There are limited players, and the product's going to be there forever.

It kind of validates our thesis on insulin. Again, it also tells you that it takes a long time to develop it unless you're fully integrated and have the scale that we've built over decades.

Being successful is not just having a product or an approval. You need to be consistent.

You need to be in a position to have fermentation capability, the drug product capability, device capability, navigate the IP space. It's a long-term commitment, which Biocon has done over the decades, and we're committed to this business.

Thank you so much.

Thanks, Michelle. Thank you, everyone, for joining the call.

If you have any additional questions, please get in touch with the IR team, and we'll be happy to address them. Thank you.